CVS Health's Medicaid business is experiencing medical cost pressure from higher-than-expected acuity following the resumption of member redeterminations.
Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.
Legislation slowly wending its way through states and in Washington could mean increased payments to drugstore chains like CVS Health, Walgreens, Walmart and independent pharmacies across the country.
In the latest trading session, CVS Health (CVS) closed at $44.36, marking a +1.32% move from the previous day.
TD Cowen keeps a Buy rating and $80 price target on CVS. The firm says the DOJ complaint relating to opioid prescriptions is incremental to the 2022 settlement with state and local governments for $5B over 10 years. The multi-year impasse between the DOJ and CVS suggests CVS is confident in its case, and while it is unclear what a final settlement figure may be, it may be a fraction of the $5B 10-year settlement that CVS came to with state and local governments in 2022, the analyst tells investors in a research note.
The U.S. Department of Justice announced a lawsuit against CVS. Transcript: Conway Gittens: There's a rebound on Wall Street Thursday, one-day after stocks suffered their biggest drops since August.
CNBC's Jim Cramer delivers his daily Mad Dash.
Investors feel optimistic about CVS Health's 2025 roadmap. Yet, poor macroeconomic conditions are concerning.
CVS Health Corp (NYSE:CVS) has been accused by the US Department of Justice of violating the Controlled Substances Act (CSA) and the False Claims Act (FCA). A lawsuit filed in Rhode Island claims CVS knowingly knowingly filled prescriptions for opioids that lacked legitimate medical purposes.
The U.S. Department of Justice on Wednesday announced a lawsuit accusing CVS of filling and billing federal health insurance programs for illegal opioid prescriptions.
CVS's stock was headed to its biggest monthly loss in 23 years, as Donald Trump vowed to “knock out” the pharmacy middleman.
CVS Health (CVS) stock price continued its strong downward trend as the company's woes accelerated. Most recently, it has dropped in the last three consecutive weeks, moving to a low of $46.60, its lowest level since March 2020.